Status:
COMPLETED
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
GE Healthcare
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison o...
Detailed Description
Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at Mayo Clinic will be eligible.
Eligibility Criteria
Inclusion
- Clinically and echocardiographically defined hypertrophic cardiomyopathy.
- Clinically indicated transthoracic echocardiography as part of the medical evaluation.
- No contradiction to administration of ultrasonic echocardiography contrast.
- Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
- No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
- Age 18 years and older
Exclusion
- 1\) Insufficient image quality for determination of maximal wall thickness.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2017
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT02234336
Start Date
October 1 2014
End Date
July 25 2017
Last Update
February 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905